Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Back
Share this video  

iwMyeloma 2018 | Cereblon pathway-mediated IMiD resistance in multiple myeloma

Constantine Mitsiades • 7 Sep 2018
iwMyeloma 2018
Multiple Myeloma Lenalidomide Pomalidomide Thalidomide

CRISPR technology is being used to define mechanisms of multiple myeloma (MM) drug resistance. Here, Constantine Mitsiades, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses his group’s work in this exciting area, investigating Cereblon pathway-mediated resistance to thalidomide and its derivatives, lenalidomide and pomalidomide. He concludes by highlighting what can be done in future trials to select patients who do not have this resistance. This interview took place at the Myeloma 2018 meeting, held in San Diego, CA.

More from Constantine Mitsiades

1:40
Highlights from IMS 2023: integrating multi-omic technologies & understanding resistance
Constantine Mitsiades • 29 Sep 2023
1:37
Using CRISPR technology to identify genes preferentially essential for multiple myeloma cells
Constantine Mitsiades • 29 Sep 2023
8:43
Highlights from the IMW 2021 meeting
Constantine Mitsiades • 11 Sep 2021
13:23
Novel therapeutics in multiple myeloma
Christoph Driessen et al. • 18 Oct 2017

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals